Glucose Homeostasis
Gluconeogenesis: Pushing Glucose Back Uphill
Gluconeogenesis is how the body builds glucose from scratch when food runs out, and its single organizing idea is that it is not glycolysis run backward. It shares seven near-equilibrium enzymes with glycolysis but routes around the three irreversible glycolytic steps with four different enzymes, working across three compartments and paying real ATP to climb a thermodynamic hill. The same fructose-2,6-bisphosphate switch that turns glycolysis on turns gluconeogenesis off, so a healthy cell almost never runs both at once.
Skip breakfast and lunch, and somewhere in the early afternoon your liver starts building glucose out of spare parts. It has to. Your brain runs almost entirely on glucose, and your red blood cells run on nothing else, because they have no mitochondria. Stored glycogen covers maybe twelve hours. After that, blood sugar stays in its narrow lane (about 70–100 mg/dL fasting) only because the liver, and in a long fast the kidney cortex, is manufacturing fresh glucose. That manufacturing pathway is gluconeogenesis.
Fasting itself is old and human. The Teton Sioux fasted to invite a spiritual awakening, and cultures across the world still fast for clarity or devotion. Your brain does not care about enlightenment; it cares about glucose, and it will get it. Fasting is not the same as running out of energy. Your body is switching fuel sources, and gluconeogenesis is the switch that keeps the most glucose-dependent tissues supplied while everything else learns to burn fat.
Three ways to build a sugar
Gluconeogenesis assembles glucose from non-carbohydrate precursors, and there are three to know. Lactate comes back from hard-working muscle and red cells; lactate dehydrogenase converts it to pyruvate. Glucogenic amino acids, alanine chief among them, enter at pyruvate or at oxaloacetate after losing their nitrogen. Glycerol, released when fat is mobilized, enters as DHAP by way of glycerol kinase and glycerol-3-phosphate dehydrogenase.
Notice what is missing from that list: fat itself. This trips up almost everyone, so hold onto it. Even-chain fatty acids cannot become glucose. Their carbons enter the citric acid cycle as acetyl-CoA, but for every acetyl-CoA that comes in, two carbons leave as CO₂. You spend one oxaloacetate to bring acetyl-CoA into the cycle and you get exactly one back. Net oxaloacetate gain is zero, so net glucose from fat is zero. The one exception is odd-chain fatty acids, whose final three-carbon propionyl-CoA can be routed through succinyl-CoA to oxaloacetate. That is the whole reason “you can’t turn fat into sugar” is true for the fat you actually carry.
The trap: is this just glycolysis in reverse?
No. This is the single most important idea in the chapter. Gluconeogenesis shares seven of its enzymes with glycolysis, the near-equilibrium ones that run happily in either direction. But glycolysis has three irreversible, energy-dumping steps, and you cannot simply push those backward. So gluconeogenesis routes around all three with four different enzymes, in different compartments, at real energetic cost.
The three walls and their bypasses: pyruvate kinase is bypassed by pyruvate carboxylase plus PEPCK; phosphofructokinase-1 is bypassed by fructose-1,6-bisphosphatase; and hexokinase is bypassed by glucose-6-phosphatase. Different enzymes, different doors, same map run as opposite traffic.
Bypass 1: the shipping problem
The first wall is the most elaborate, and it spans two compartments. Inside the mitochondrion, pyruvate carboxylase adds CO₂ to pyruvate to make oxaloacetate, spending one ATP. It uses a biotin cofactor mounted on a roughly 14-Å lysine arm that swings the carboxyl group into place, and it is allosterically switched on by acetyl-CoA, the cell’s way of saying plenty of fuel here, make glucose rather than burn more pyruvate.
Then comes the shipping problem. PEPCK, the enzyme that takes the next step, lives in the cytosol, and oxaloacetate has no transporter across the inner mitochondrial membrane. The fix is the malate shuttle: oxaloacetate is reduced to malate, malate rides out on the malate–α-ketoglutarate carrier, and in the cytosol it is oxidized back to oxaloacetate. The trip does double duty, exporting the carbon skeleton and (for pyruvate or alanine precursors) carrying the NADH that GAPDH will need later. Then PEPCK spends a GTP and removes the very CO₂ that pyruvate carboxylase added, producing phosphoenolpyruvate. That carboxylate-then-decarboxylate move is a thermodynamic lever: adding CO₂ and pulling it back off is what makes forming high-energy PEP favorable.
Bypasses 2 and 3, and why muscle can’t share
From PEP, the shared enzymes run in reverse up to fructose-1,6-bisphosphate. There FBPase-1 simply hydrolyzes off a phosphate, with no ATP made or spent, a clean snip past the PFK-1 wall. It is the main regulated step of the pathway, inhibited by AMP and by fructose-2,6-bisphosphate.
The last wall, glucose-6-phosphatase, hides in a revealing place: the lumen of the endoplasmic reticulum. Glucose-6-phosphate has to be carried in by the T1 transporter to be dephosphorylated. Why tuck it away there? Because hexokinase sits in the cytosol running the opposite reaction, and keeping the two enzymes in separate rooms prevents a futile cycle. Only liver and kidney cortex express G6Pase. Muscle does not, which means muscle can never release free glucose into the blood. It hoards what it makes and ships out lactate instead, and that single missing enzyme is the reason the Cori cycle has to exist.
The Cori cycle makes no new energy — it relocates the bill. A sprinting muscle outruns its oxygen and can only make ATP by fermenting glucose to lactate; shipping that lactate to the liver lets a tissue that still has oxygen pay the 6-ATP cost of rebuilding glucose. That deferred cost is part of why you keep breathing hard after the sprint ends.
Mitochondrial. A biotin cofactor on a swinging ~14-Å lysine arm carries the added CO₂. The enzyme is switched on only when acetyl-CoA is high — the cell's signal that fuel is plentiful and it should build glucose, not burn more pyruvate.
Regulation. Allosterically activated by acetyl-CoA; this is the anaplerotic gate into gluconeogenesis.
Clinical. Pyruvate carboxylase deficiency gives one enzyme but two findings: hypoglycemia (no OAA to start) and lactic acidosis (pyruvate shunted to lactate).
OAA can't cross the inner membrane, so it is reduced to malate, ferried out on the malate–α-ketoglutarate carrier, and re-oxidized to OAA in the cytosol. With pyruvate or alanine precursors this relocation also supplies the NADH GAPDH will need; with lactate, LDH already made that NADH and OAA can leave as aspartate. The reducing power was spent in the matrix making malate, so it is moved, not minted — no free NADH credit here.
Cytosolic. Removes the very CO₂ pyruvate carboxylase just added. That carboxylation-then-decarboxylation pair is a thermodynamic lever that makes forming high-energy PEP favorable. Spends a GTP, tracked here as a high-energy phosphate.
Clinical. In insulin resistance, PEPCK transcription is no longer suppressed, so hepatic gluconeogenesis runs unchecked and feeds fasting hyperglycemia.
A near-equilibrium glycolytic enzyme run in reverse, a hydration this direction. No new enzyme needed.
Shared and reversible. Moves the phosphate from C2 back to C3.
Runs the substrate-level step in reverse, so here it COSTS an ATP rather than making one. This is one of the places gluconeogenesis pays for fighting gravity.
Consumes the cytosolic NADH, reducing the acyl-phosphate back to an aldehyde. This is the reductive step the malate shuttle was feeding.
Two trioses condense back into one six-carbon sugar, the mirror of the aldolase cleavage in glycolysis. Glycerol enters here, as DHAP.
A simple hydrolysis that lops off the C1 phosphate, bypassing irreversible PFK-1. This is the main regulated step: inhibited by AMP and by fructose-2,6-bisphosphate, activated by citrate.
Regulation. Fructose-2,6-bisphosphate is the master inhibitor — high when fed, low when fasting.
Clinical. FBPase-1 deficiency causes fasting hypoglycemia and lactic acidosis in infants, especially when sick.
Shared and reversible. Ketose back to aldose.
Hydrolysis in the ER lumen, deliberately separated from cytosolic hexokinase to avoid a futile cycle; the T1 transporter carries G6P in. Only liver and kidney cortex express it, which is why muscle cannot release free glucose and ships out lactate instead.
Clinical. Von Gierke disease (glycogen storage disease type I): loss of G6Pase or its transporter gives severe fasting hypoglycemia, lactic acidosis, and a glycogen-laden liver.
The bill, and the switch that prevents waste
Walk the cost meter up the island and it lands on 4 ATP + 2 GTP + 2 NADH per glucose. Glycolysis nets only 2 ATP. Building is far more expensive than breaking, exactly as you would expect. Glycolysis runs downhill the way gravity pulls water; gluconeogenesis is the pump that pushes it back up, and pumps cost energy because they fight thermodynamics.
That expense is why the cell must never run both pathways at once, because doing so would just spin ATP into heat. The guard against this is reciprocal regulation at the three enzyme pairs, and its master switch is fructose-2,6-bisphosphate. Lock in the distinction: fructose-1,6-bisphosphate is a pathway intermediate, while fructose-2,6-bisphosphate is a regulator only. 1,6 is the pathway; 2,6 is the regulator. Both are made by the bifunctional PFK-2/FBPase-2 enzyme, a single protein carrying a kinase domain and a phosphatase domain. When you are fed, insulin keeps it dephosphorylated, the kinase wins, F-2,6-BP rises, and glycolysis runs. When you fast, glucagon raises cAMP, PKA phosphorylates the enzyme, the phosphatase wins, F-2,6-BP falls, and gluconeogenesis takes over. PKA also shuts off liver pyruvate kinase, closing the door behind you.
The clinic makes all of this concrete. Pyruvate carboxylase deficiency produces hypoglycemia and lactic acidosis together, one missing enzyme and two findings, because pyruvate can neither start gluconeogenesis nor stop piling up as lactate. In type 2 diabetes, insulin resistance lifts the brake on PEPCK, hepatic gluconeogenesis runs unchecked, and fasting blood sugar climbs; metformin works largely by activating AMPK to rein it back in. And the interorgan loops tie the body together. The Cori cycle sends muscle lactate to the liver to be rebuilt into glucose, with the liver paying the ATP bill, while the alanine cycle carries muscle nitrogen to the liver safely packaged on alanine, because muscle lacks the urea-cycle machinery to dispose of ammonia on its own. A rising serum ALT, the very enzyme that runs the alanine cycle, is a clinic’s flag for liver damage.
In the next chapter we follow pyruvate the other way, into the mitochondrion, where the pyruvate dehydrogenase complex commits it to the citric acid cycle and acetyl-CoA finally gets fully burned.
How we measure it
Isotopic carbon tracing of precursors
Feed a precursor labeled at a known carbon — ¹⁴C-lactate, ¹³C-alanine, or ¹³C-glycerol — and track where the atoms land in newly made glucose. The carbon skeleton is what becomes glucose (alanine's nitrogen is stripped by transamination first), so the label has to sit on carbon. This is how the field proved the fact at the heart of the chapter: carbons from even-chain fatty acids never reach glucose, because the two that enter the cycle as acetyl-CoA leave again as CO₂.
Stable-isotope tracing of glucose production
To measure how much glucose the liver is making, infuse a labeled glucose tracer in an overnight-fasted (basal) subject and read the dilution: total glucose appearance minus any infused glucose is endogenous glucose production, mostly gluconeogenesis. A hyperinsulinemic-euglycemic clamp answers a different question — it raises insulin to see how well it SUPPRESSES that output, so failure to suppress is the read-out of hepatic insulin resistance, not a measure of fasting gluconeogenesis itself.
Allosteric enzyme assay with single effectors
To map a control point you purify the enzyme and change one effector at a time while watching velocity. Adding acetyl-CoA to pyruvate carboxylase, AMP or fructose-2,6-bisphosphate to FBPase-1, or running the bifunctional PFK-2/FBPase-2 enzyme with and without PKA phosphorylation is how the reciprocal regulators of this pathway were assigned to their enzymes, one molecule at a time.